Aflatoxin, Hepatitis and Worldwide Liver Cancer Risks

  • Sara H. Henry
  • F. Xavier Bosch
  • J. C. Bowers
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 504)


Aflatoxins are among the most potent mutagenic and carcinogenic substances known. Differential potency of aflatoxin among species can be partially attributed to differences in metabolism; however, current information on competing aspects of metabolic activation and detoxification of aflatoxin in various species does not identify an adequate animal model for humans. Risk of liver cancer is influenced by a number of factors, most notably carriage of hepatitis B virus as determined by the presence in serum of the hepatitis B surface antigen (HBsAg+ or HBsAg-). About 50 to 100% of liver cancer cases are estimated to be associated with persistent infection of hepatitis B (or C) virus. The potency of aflatoxin in HBsAg+ individuals is substantially higher (about a factor of 30) than the potency in HBsAg-individuals. Thus, reduction of the intake of aflatoxins in populations with a high prevalence of HBsAg+ individuals will have greater impact on reducing liver cancer rates than reductions in populations with a low prevalence of HbsAg+ individuals. The present analysis suggests that vaccination against hepatitis B (or protection against hepatits C), which reduces prevalence of carriers, would reduce the potency of the aflatoxins in vaccinated populations and reduce liver cancer risk.


Liver Cancer Pool Urine Sample Aflatoxin Exposure Liver Cancer Case Adequate Animal Model 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alter, M.J, 1996, Epidemiology of hepatitis C.Eur. J. Gastroenterol. Hepatol.8:319.CrossRefGoogle Scholar
  2. Bosch, F.X., Ribes, J., and Borras, J., 1999, Epidemiology of primary liver cancer in:Seminars in Liver Disease19(3):271.CrossRefGoogle Scholar
  3. Chi, W.J., Doong, S.-L., Lin-Shiau, S.-Y., Boone, C.W., Kellloff, G.J., and Lin, J., 1998, Oltipraz, a novel inhibitor of hepatitis B virus transcription through elevation of p53 protein.Carcinogenesis19(12): 2133.CrossRefGoogle Scholar
  4. Deurric, S., Poynard, T., Buffet, L., and Valleron, A.-J., 1998, Trends in primary liver cancer.The Lancet351:215.Google Scholar
  5. El-Serag, H.B. and Mason, A.C., 2000, Rsisk factors for the rising rates of hepatocellular carcinoma in the United States.Gastroenterol. 118(4): Suppl 2. 3792.Google Scholar
  6. Gay, N.J., and Edmonds, W.J., 1998, Developed countries could pay for hepatitis B vaccination in developing countries.Brit. Med. J.316:1457.CrossRefGoogle Scholar
  7. Hoofnagle, J.H., 1997, Hepatitis C: the clinical spectrum of disease.Hepatol. 26:155.CrossRefGoogle Scholar
  8. IARC, 1994, Hepatitis viruses, Monographs on the evaluation of carcinogenic risks to humans. IARC Sci. Publ. 59. Lyon, France.Google Scholar
  9. JECFA, 1998, Aflatoxins. Safety evaluation of certain food additives and contaminants. (The forty-ninth meeting of the Joint FAO/WHO Expert Committee on Food Additives.). WHO Food Additives Series, no. 40. World Health Organization, Geneva 1998. pp 359–468.Google Scholar
  10. Kensler, T.W., He, X., Otieno, M., Egner, P.A., Jacobson, L.P., Chen, B., Wang, J.S., Zhu, Y.R., Zhang, B.C., 1998, Oltipraz chemoprevention trial in Qidong, People’s Republic of China: modulation of serum aflatoxin albumin adduct biomarkers.Cancer Epidemiol. Biomarkers Prey.7:127.Google Scholar
  11. Lee, M.-S., Kim, D.-H., Kim, H., Lee, H.-S., Kim, C.-Y., Park, T.-S., Yoo, K.-Y., Park, B.-J., and Alm, Y-O., 1998, Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea.Int. J of Epidem.27:316.CrossRefGoogle Scholar
  12. Parkin, D.M., 1998, The global burden of cancerSemin. Cancer Biol.8:219.CrossRefGoogle Scholar
  13. Sun, Z., Lu, P., Gail, M.H., Pee, D., Zhang Q Ming, L., Wang, J., Wu, Y., Liu, G., Wu, Y., and Zhu, Y., 1999, Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite MI.Hepatol.30:379.CrossRefGoogle Scholar
  14. Wang, J.S., Qian, G.S., Zarba, A., He, X., Zhu, Y.R., Zhang, B.C., Jacobson, L., Gange, S.J., Munoz, A., Kensler, T.W., 1996, Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen positive and antigen-negative residents of Daxin, Qidong County, People’s Republic of China.Cancer Epidemiol. Biomarkers Prey.5:253–261.Google Scholar
  15. Wang, J.S., Shen, X., He, X., Zhu, B.C., Zhang, B.C., Wang, J.B., Qian, G.S., Kuang, S.Y., Zarba, A., Egner, P.A., 1999, Protective alterations in phase 1 and 2 metabolism of aflatoxin B I by oltipraz in residents of Qidong, People’s Republic of China.JNCI91:347–354.CrossRefGoogle Scholar
  16. Wild, C.P., and Hall, A.J., 2000, Primary prevention of hepatocellular carcinoma in developing countries.Mut. Res.462:381.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Sara H. Henry
    • 1
  • F. Xavier Bosch
    • 2
  • J. C. Bowers
  1. 1.U.S. Food and Drug Administration
  2. 2.lnstitut d’ Oncologia Hospitalet del LlobregatBarcelonaSpain

Personalised recommendations